Review of the marketing history of Darolutamide tablets: Analysis of market dynamics and impact

Darolutamide, a new androgen receptor antagonist jointly developed by Germany's Bayer and Finland's Orion, is opening a new chapter in the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC). Its unique chemical structure design allows it to effectively block androgen receptors while reducing the permeability to the central nervous system, thus reducing the impact on the patient's quality of daily life.

In July 2019, darotamide was approved by the US FDA for the first time, bringing new hope to patients with nmCRPC. Subsequently, the European Union, Japan and other places also successively approved its listing, and it is widely used around the world. In China, the launch of darotamide has also attracted much attention. According to the latest predictions from the Insight database, the National Medical Products Administration (NMPA) has officially approved its marketing application, filling a gap in the domestic nmCRPC treatment field.

Data from the ARAMIS pivotal clinical trial showed that compared with placebo, darotamide significantly prolonged the metastasis-free survival (MFS) and overall survival (OS) of patients, and had excellent safety performance. This positive result provides a solid basis for its global launch.
Prostate cancer is a common malignant tumor in men, and patients with nmCRPC have limited treatment options and severe side effects. The advent of darotamide has brought new treatment options to these patients. Its excellent efficacy and safety are expected to improve patients' quality of life and extend their life.
As the global population ages, the incidence of prostate cancer continues to rise. As an innovative drug, darotamide has huge market demand potential. In China, as medical standards improve and patients' demand for new treatment options increases, the launch of darotamide has broad prospects and is expected to achieve excellent market performance and bring good news to more patients.
Reference:
https://www.ema.europa.eu/en/medicines/human/EPAR/nubeqa